Biogen (HAM:IDP) Selling, General, & Admin. Expense

: €2,237 Mil (TTM As of Jun. 2023)

View and export this data going back to 2001. Start your Free Trial

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Biogen's selling, general, & admin. expense for the three months ended in Jun. 2023 was €506 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Jun. 2023 was €2,237 Mil.

Biogen Selling, General, & Admin. Expense Historical Data

The historical data trend for Biogen's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Selling, General, & Admin. Expense

1,851.44

2,137.23

2,058.70

2,366.76

2,269.00

Biogen Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Selling, General, & Admin. Expense																541.68	568.93	597.36	565.07	505.80

Competitive Comparison

For the Drug Manufacturers - General subindustry, Biogen's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

Biogen Selling, General, & Admin. Expense Distribution

For the Drug Manufacturers industry and Healthcare sector, Biogen's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Biogen's Selling, General, & Admin. Expense falls in comparison to its industry or sector. The grey bar indicates the Selling, General, & Admin. Expense's extreme value range as defined by GuruFocus.

Biogen Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €2,237 Mil.

Biogen (HAM:IDP) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.

Biogen Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of Biogen's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen (HAM:IDP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (HAM:IDP) » Definitions » Selling, General, & Admin. Expense

Comparable Companies

Traded in Other Exchanges

BIIB:USA BIIB:Mexico IDP:Germany IDP:Germany IDP:Germany BIIB34:Brazil BIIB:Austria BIIB:Argentina

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

https://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (HAM:IDP) Headlines

No Headlines